Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges

On Tuesday, Mural Oncology plc MURA released data from the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck & Co Inc’s MRK Keytruda (pembrolizumab) vs. investigator choice single agent chemotherapy for platinum-resistant ovarian cancer.

The company said it would not continue the final analysis and would cease the development of nemvaleukin for platinum-resistant ovarian cancer. 

In the pre-specified interim analysis conducted by the independent data monitoring committee, nemvaleukin, in combination with pembrolizumab, did not achieve a statistically significant improvement in overall survival versus the investigator’s choice of chemotherapy alone.

Mural Oncology says the study is highly unlikely to achieve success at the final analysis.

Also Read: Which Stocks Benefit From AI Spending? Analyst Names IBM And More

Median overall survival was 10.1 months for patients treated with nemvaleukin in combination with pembrolizumab and 9.8 months for patients treated with investigator’s choice chemotherapy (hazard ratio: 0.98).

Nemvaleukin has a well-characterized and favorable safety profile, both as a monotherapy and in combination with pembrolizumab. Over 800 patients were treated across the broader clinical program.

In the interim analysis of ARTISTRY-7, the safety profile was generally consistent with previously reported data.

Nemvaleukin is being evaluated in a potentially registrational phase 2 trial, ARTISTRY-6, cohort 2, in mucosal melanoma. The topline data readout is expected in Q2 2025.

The preliminary data readouts for less-frequent intravenous dosing of nemvaleukin in patients with cutaneous melanoma are expected in the second quarter of 2025 for cohort 3 of ARTISTRY-6 (monotherapy) and the second half of 2025 for cohort 4 of ARTISTRY-6 (combination therapy).

Price Action: MURA stock is down 49.6% at $1.93 during the premarket session at the last check Tuesday.

Read Next:

• Shell Unveils New Strategy: Higher Buybacks, Cost Cuts And 10% Annual Free Cash Flow Growth

Photo: Shutterstock